1
|
Fourati S, Dumay A, Roy M, Willemetz A, Ribeiro-Parenti L, Mauras A, Mayeur C, Thomas M, Kapel N, Joly F, Le Gall M, Bado A, Le Beyec J. Fecal microbiota transplantation in a rodent model of short bowel syndrome: A therapeutic approach? Front Cell Infect Microbiol 2023; 13:1023441. [PMID: 36936775 PMCID: PMC10020656 DOI: 10.3389/fcimb.2023.1023441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Accepted: 02/03/2023] [Indexed: 03/06/2023] Open
Abstract
Extensive intestinal resection leads to Short Bowel Syndrome (SBS), the main cause of chronic intestinal failure. Colon preservation is crucial for spontaneous adaptation, to improve absorption and reduce parenteral nutrition dependence. Fecal microbiota transplantation (FMT), a promising approach in pathologies with dysbiosis as the one observed in SBS patients, was assessed in SBS rats with jejuno-colonic anastomosis. The evolution of weight and food intake, the lenght of intestinal villi and crypts and the composition of fecal microbiota of Sham and SBS rats, transplanted or not with high fat diet rat microbiota, were analyzed. All SBS rats lost weight, increased their food intake and exhibited jejunal and colonic hyperplasia. Microbiota composition of SBS rats, transplanted or not, was largely enriched with Lactobacillaceae, and α- and β-diversity were significantly different from Sham. The FMT altered microbiota composition and α- and β-diversity in Sham but not SBS rats. FMT from high fat diet rats was successfully engrafted in Sham, but failed to take hold in SBS rats, probably because of the specific luminal environment in colon of SBS subjects favoring aero-tolerant over anaerobic bacteria. Finally, the level of food intake in SBS rats was positively correlated with their Lactobacillaceae abundance. Microbiota transfer must be optimized and adapted to this specific SBS environment.
Collapse
Affiliation(s)
- Salma Fourati
- UMR-S1149, Centre de recherche sur l’inflammation, INSERM, Universite Paris Cite, Paris, France
- Sorbonne Université, AP-HP, Hôpital de la Pitié‐Salpêtrière‐Charles Foix, Service de Biochimie Endocrinienne et Oncologique, Paris, France
- Paris Center for Microbiome Medicine, Federation Hospitalo-Universitaire, Paris, France
| | - Anne Dumay
- UMR-S1149, Centre de recherche sur l’inflammation, INSERM, Universite Paris Cite, Paris, France
| | - Maryline Roy
- UMR-S1149, Centre de recherche sur l’inflammation, INSERM, Universite Paris Cite, Paris, France
| | - Alexandra Willemetz
- UMR-S1149, Centre de recherche sur l’inflammation, INSERM, Universite Paris Cite, Paris, France
| | - Lara Ribeiro-Parenti
- UMR-S1149, Centre de recherche sur l’inflammation, INSERM, Universite Paris Cite, Paris, France
- AP-HP, Hôpital Bichat -Claude Bernard, Service de chirurgie Générale OEsogastrique et Bariatrique, Paris, France
| | - Aurélie Mauras
- Paris Center for Microbiome Medicine, Federation Hospitalo-Universitaire, Paris, France
- UMR1319 - Micalis Institute, Institut National de Recherche pour l’Agriculture, l’alimentation et l’environnement (INRAE), AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France
| | - Camille Mayeur
- Paris Center for Microbiome Medicine, Federation Hospitalo-Universitaire, Paris, France
- UMR1319 - Micalis Institute, Institut National de Recherche pour l’Agriculture, l’alimentation et l’environnement (INRAE), AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France
| | - Muriel Thomas
- Paris Center for Microbiome Medicine, Federation Hospitalo-Universitaire, Paris, France
- UMR1319 - Micalis Institute, Institut National de Recherche pour l’Agriculture, l’alimentation et l’environnement (INRAE), AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France
| | - Nathalie Kapel
- Paris Center for Microbiome Medicine, Federation Hospitalo-Universitaire, Paris, France
- UMR-S 1139, INSERM, Universite Paris Cite, Paris, France
- AP-HP, Hôpital de la Pitié‐Salpêtrière‐Charles Foix, Service de Coprologie fonctionnelle, Paris, France
| | - Francisca Joly
- UMR-S1149, Centre de recherche sur l’inflammation, INSERM, Universite Paris Cite, Paris, France
- Department of gastroenterology, IBD and nutrition Support, AP‐HP, CRMR MarDi, Hôpital Beaujon, Clichy, France
| | - Maude Le Gall
- UMR-S1149, Centre de recherche sur l’inflammation, INSERM, Universite Paris Cite, Paris, France
| | - André Bado
- UMR-S1149, Centre de recherche sur l’inflammation, INSERM, Universite Paris Cite, Paris, France
| | - Johanne Le Beyec
- UMR-S1149, Centre de recherche sur l’inflammation, INSERM, Universite Paris Cite, Paris, France
- Sorbonne Université, AP-HP, Hôpital de la Pitié‐Salpêtrière‐Charles Foix, Service de Biochimie Endocrinienne et Oncologique, Paris, France
- Paris Center for Microbiome Medicine, Federation Hospitalo-Universitaire, Paris, France
- *Correspondence: Johanne Le Beyec, ;;
| |
Collapse
|
2
|
Collard MK, Tourneur-Marsille J, Uzzan M, Albuquerque M, Roy M, Dumay A, Freund JN, Hugot JP, Guedj N, Treton X, Panis Y, Ogier-Denis E. The Appendix Orchestrates T-Cell Mediated Immunosurveillance in Colitis-Associated Cancer. Cell Mol Gastroenterol Hepatol 2023; 15:665-687. [PMID: 36332814 PMCID: PMC9871441 DOI: 10.1016/j.jcmgh.2022.10.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2021] [Revised: 10/11/2022] [Accepted: 10/20/2022] [Indexed: 11/06/2022]
Abstract
BACKGROUND & AIMS Although appendectomy may reduce colorectal inflammation in patients with ulcerative colitis (UC), this surgical procedure has been suggested to be associated with an increased risk of colitis-associated cancer (CAC). Our aim was to explore the mechanism underlying the appendectomy-associated increased risk of CAC. METHODS Five-week-old male BALB/c mice underwent appendectomy, appendicitis induction, or sham laparotomy. They were then exposed to azoxymethane/dextran sodium sulfate (AOM/DSS) to induce CAC. Mice were killed 12 weeks later, and colons were taken for pathological analysis and immunohistochemistry (CD3 and CD8 staining). Human colonic tumors from 21 patients with UC who underwent surgical resection for CAC were immunophenotyped and stratified according to appendectomy status. RESULTS Whereas appendectomy significantly reduced colitis severity and increased CAC number, appendicitis induction without appendectomy led to opposite results. Intratumor CD3+ and CD8+ T-cell densities were lower after appendectomy and higher after appendicitis induction compared with the sham laparotomy group. Blocking lymphocyte trafficking to the colon with the anti-α4β7 integrin antibody or a sphingosine-1-phosphate receptor agonist suppressed the inducing effect of the appendectomy on tumors' number and on CD3+/CD8+ intratumoral density. CD8+ or CD3+ T cells isolated from inflammatory neo-appendix and intravenously injected into AOM/DSS-treated recipient mice increased CD3+/CD8+ T-cell tumor infiltration and decreased tumor number. In UC patients with a history of appendectomy, intratumor CD3+ and CD8+ T-cell densities were decreased compared with UC patients without history of appendectomy. CONCLUSIONS In UC, appendectomy could suppress a major site of T-cell priming, resulting in a less efficient CAC immunosurveillance.
Collapse
Affiliation(s)
- Maxime K Collard
- Assistance Publique Hôpitaux de Paris, Service de Chirurgie Colorectale, Hôpital Beaujon, Clichy, France; Université de Paris, Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, "Gut Inflammation", Paris, France
| | - Julien Tourneur-Marsille
- Université de Paris, Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, "Gut Inflammation", Paris, France
| | - Mathieu Uzzan
- Université de Paris, Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, "Gut Inflammation", Paris, France; Assistance Publique Hôpitaux de Paris, Service de Gastroentérologie, Hôpital Beaujon, Clichy, France
| | - Miguel Albuquerque
- Assistance Publique Hôpitaux de Paris, Service d'Anatomopathologie, Hôpital Beaujon, Clichy, France
| | - Maryline Roy
- Université de Paris, Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, "Gut Inflammation", Paris, France
| | - Anne Dumay
- Université de Paris, Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, "Gut Inflammation", Paris, France
| | - Jean-Noël Freund
- Université de Strasbourg, Inserm, IRFAC / UMR-S1113, FHU ARRIMAGE, ITI InnoVec, FMTS, Strasbourg, France
| | - Jean-Pierre Hugot
- Université de Paris, Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, "Gut Inflammation", Paris, France
| | - Nathalie Guedj
- Université de Paris, Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, "Gut Inflammation", Paris, France; Assistance Publique Hôpitaux de Paris, Service d'Anatomopathologie, Hôpital Beaujon, Clichy, France
| | - Xavier Treton
- Université de Paris, Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, "Gut Inflammation", Paris, France; Assistance Publique Hôpitaux de Paris, Service de Gastroentérologie, Hôpital Beaujon, Clichy, France
| | - Yves Panis
- Assistance Publique Hôpitaux de Paris, Service de Chirurgie Colorectale, Hôpital Beaujon, Clichy, France; Université de Paris, Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, "Gut Inflammation", Paris, France
| | - Eric Ogier-Denis
- Université de Paris, Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, "Gut Inflammation", Paris, France; INSERM, Université Rennes, CLCC Eugène Marquis, «Chemistry, Oncogenesis, Stress Signaling» UMR_S 1242, Rennes, France.
| |
Collapse
|
3
|
Abstract
Crohn's disease [CD] is an inflammatory bowel disease of unknown aetiology. During recent decades, significant technological advances led to development of -omic datasets allowing a detailed description of the disease. Unfortunately these have not, to date, resolved the question of the aetiology of CD. Thus, it may be necessary to [re]consider hypothesis-driven approaches to resolve the aetiology of CD. According to the cold chain hypothesis, the development of industrial and domestic refrigeration has led to frequent exposure of human populations to bacteria capable of growing in the cold. These bacteria, at low levels of exposure, particularly those of the genus Yersinia, are believed to be capable of inducing exacerbated inflammation of the intestine in genetically predisposed subjects. We discuss the consistency of this working hypothesis in light of recent data from epidemiological, clinical, pathological, microbiological, and molecular studies.
Collapse
Affiliation(s)
- Jean-Pierre Hugot
- Centre de recherche sur l’inflammation, UMR1149 INSERM and Université de Paris, Paris, France,Service des maladies digestives et respiratoires de l’enfant, Hôpital Robert Debré, Assistance Publique Hôpitaux de Paris, Paris, France,Corresponding author: Jean-Pierre Hugot, MD, PhD, Service des maladies digestives et respiratoires de l’enfant, Hôpital Robert Debré, 48 Bd Sérurier, F75019 Paris, France. Tel.: [33] 1 40 03 57 12; fax: [33] 1 40 03 57 66;
| | - Anne Dumay
- Centre de recherche sur l’inflammation, UMR1149 INSERM and Université de Paris, Paris, France
| | - Frédérick Barreau
- IRSD, UMR1220, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France
| | - Ulrich Meinzer
- Centre de recherche sur l’inflammation, UMR1149 INSERM and Université de Paris, Paris, France,Service des maladies digestives et respiratoires de l’enfant, Hôpital Robert Debré, Assistance Publique Hôpitaux de Paris, Paris, France
| |
Collapse
|
4
|
Abstract
BACKGROUND AND AIMS Nucleotide Oligomerisation Domain 2 [NOD2] is a key gene of innate immunity which participates in the host defence against pathogens. Several loss-of-function NOD2 mutations are associated with Crohn's disease [CD]. Their high frequencies in populations of European ancestry suggest a model of balancing selection. Because NOD2 deficiency has been associated with a resistance to Yersinia pseudotuberculosis in mice, we hypothesised that NOD2 mutations have been selected during past plague outbreaks due to the closely related bacterium Yersinia pestis. METHODS Contemporary frequencies of the main CD-associated NOD2 mutations [R702W, G908R, and 1007fs], measured in healthy people from European and Mediterranean countries, were collected from 60 studies via a PubMed search. Plague exposure was calculated from a dataset providing outbreaks from 1346 to 1860 in Europe and the Mediterranean Bassin. A plague index was built to capture the intensity of plague exposure in the studied geographical areas. RESULTS NOD2 mutation frequencies were associated with the past exposure to plague. Statistical significance was obtained for the most frequent mutation [R702W, p = 0.03] and for the pooled three mutations [p = 0.023]. The association remained significant when putative demographic biases were considered. CONCLUSIONS This result argues for a selection of CD-associated NOD2 mutations by plague outbreaks and further questioned the role of exposure to enteropathogenic Yersinia species in CD.
Collapse
Affiliation(s)
- Anne Dumay
- Research Centre on Inflammation, UMR1149 INSERM, Université Paris Diderot, Sorbonne-Paris-Cité, Paris, France
| | - Olivier Gergaud
- KEDGE Business School, Bordeaux and LIEPP, Sciences Po, Paris, France
| | - Maryline Roy
- Research Centre on Inflammation, UMR1149 INSERM, Université Paris Diderot, Sorbonne-Paris-Cité, Paris, France
| | - Jean-Pierre Hugot
- Research Centre on Inflammation, UMR1149 INSERM, Université Paris Diderot, Sorbonne-Paris-Cité, Paris, France.,Hôpital Robert Debré, Assistance Publique Hôpitaux de Paris, DHU Unity, Paris, France
| |
Collapse
|
5
|
Le Baut G, O'Brien C, Pavli P, Roy M, Seksik P, Tréton X, Nancey S, Barnich N, Bezault M, Auzolle C, Cazals-Hatem D, Viala J, Allez M, Hugot JP, Dumay A. Prevalence of Yersinia Species in the Ileum of Crohn's Disease Patients and Controls. Front Cell Infect Microbiol 2018; 8:336. [PMID: 30298122 PMCID: PMC6160741 DOI: 10.3389/fcimb.2018.00336] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Accepted: 08/30/2018] [Indexed: 01/12/2023] Open
Abstract
Yersinia are common contaminants of food products, but their prevalence in the human gut is poorly documented. Yersinia have been implicated in Crohn's Disease (CD, an inflammatory bowel disease) however their role in CD is controversial. We performed highly sensitive PCR assays of specific sequences for the gyrB gene of Y. aldovae, Y. bercovieri, Y. enterocolitica, Y. intermedia, Y. mollaretii and the inv gene of Y. pseudotuberculosis. We analyzed a total of 470 ileal samples taken from 338 participants (262 CD patients and 76 controls) belonging to three independent cohorts. All patients and controls were phenotyped and genotyped for the main CD susceptibility variants: NOD2, ATG16L1, and IRGM. Yersinia were found in 7.7% of ileal samples (respectively 7.9 and 7.6% in controls and CD patients) corresponding to 10% of participants (respectively 11.8 and 9.5% in controls and CD patients). Y. enterocolitica, Y. pseudotuberculosis and Y. intermedia were the most frequently identified species. The bacteria were more frequent in resected specimens, lymph nodes and Peyer's patches. Yersinia were no more likely to be detected in CD tissues than tissues from inflammatory and non-inflammatory controls. CD patients treated with immunosuppressants were less likely to be Yersinia carriers. In conclusion, this work shows that Yersinia species are frequently found at low levels in the human ileum in health and disease. The role of Yersinia species in this ecosystem should now be explored.
Collapse
Affiliation(s)
- Guillaume Le Baut
- UMR1149 INSERM, Research Centre on Inflammation, Université Paris Diderot-Sorbonne Paris-Cité, Paris, France.,Department of Gastroenterology and Nutrition, Centre Hospitalier Universitaire de Caen, Caen, France
| | - Claire O'Brien
- IBD Research Group, Canberra Hospital, Canberra, ACT, Australia.,Australian National University Medical School, Canberra, ACT, Australia
| | - Paul Pavli
- IBD Research Group, Canberra Hospital, Canberra, ACT, Australia.,Australian National University Medical School, Canberra, ACT, Australia
| | - Maryline Roy
- UMR1149 INSERM, Research Centre on Inflammation, Université Paris Diderot-Sorbonne Paris-Cité, Paris, France
| | - Philippe Seksik
- Gastroenterology Unit, CNRS, INSERM, ERL 1157, LBM, APHP, Saint Antoine Hospital, Sorbonne Universités, UPMC Univ Paris 06, Ecole Normale Superieure, Paris, France
| | - Xavier Tréton
- UMR1149 INSERM, Research Centre on Inflammation, Université Paris Diderot-Sorbonne Paris-Cité, Paris, France.,Departments of Gastroenterology and Pathology, Hôpital Beaujon, Assistance Publique Hopitaux de Paris, Paris, France
| | - Stéphane Nancey
- Department of Gastroenterology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France.,INSERM U1111, International Center for Research in Infectiology, Lyon, France
| | - Nicolas Barnich
- UMR 1071 Inserm/Université d'Auvergne, USC-INRA 2018, Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), CRNH Auvergne, Clermont-Ferrand, France
| | - Madeleine Bezault
- Department of Gastroenterology, Saint-Louis Hospital, APHP, INSERM U1160, University Denis Diderot, Paris, France
| | - Claire Auzolle
- Department of Gastroenterology, Saint-Louis Hospital, APHP, INSERM U1160, University Denis Diderot, Paris, France
| | - Dominique Cazals-Hatem
- UMR1149 INSERM, Research Centre on Inflammation, Université Paris Diderot-Sorbonne Paris-Cité, Paris, France.,Departments of Gastroenterology and Pathology, Hôpital Beaujon, Assistance Publique Hopitaux de Paris, Paris, France
| | - Jérome Viala
- UMR1149 INSERM, Research Centre on Inflammation, Université Paris Diderot-Sorbonne Paris-Cité, Paris, France.,Department of Pediatric Gastroenterology, Hôpital Robert Debré, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Matthieu Allez
- Department of Gastroenterology, Saint-Louis Hospital, APHP, INSERM U1160, University Denis Diderot, Paris, France
| | | | - Jean-Pierre Hugot
- UMR1149 INSERM, Research Centre on Inflammation, Université Paris Diderot-Sorbonne Paris-Cité, Paris, France.,Department of Pediatric Gastroenterology, Hôpital Robert Debré, Assistance-Publique Hôpitaux de Paris, Paris, France
| | - Anne Dumay
- UMR1149 INSERM, Research Centre on Inflammation, Université Paris Diderot-Sorbonne Paris-Cité, Paris, France
| |
Collapse
|
6
|
van Kempen LCL, Redpath M, Elchebly M, Klein KO, Papadakis AI, Wilmott JS, Scolyer RA, Edqvist PH, Pontén F, Schadendorf D, van Rijk AF, Michiels S, Dumay A, Helbling-Leclerc A, Dessen P, Wouters J, Stass M, Greenwood CMT, Ghanem GE, van den Oord J, Feunteun J, Spatz A. The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. Sci Transl Med 2017; 8:369ra177. [PMID: 27974665 DOI: 10.1126/scitranslmed.aai9188] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2015] [Revised: 08/31/2016] [Accepted: 10/10/2016] [Indexed: 11/02/2022]
Abstract
Male gender is independently and significantly associated with poor prognosis in melanoma of all clinical stages. The biological underpinnings of this sex difference remain largely unknown, but we hypothesized that gene expression from gonosomes (sex chromosomes) might play an important role. We demonstrate that loss of the inactivated X chromosome in melanomas arising in females is strongly associated with poor distant metastasis-free survival, suggesting a dosage benefit from two X chromosomes. The gonosomal protein phosphatase 2 regulatory subunit B, beta (PPP2R3B) gene is located on the pseudoautosomal region (PAR) of the X chromosome in females and the Y chromosome in males. We observed that, despite its location on the PAR that predicts equal dosage across genders, PPP2R3B expression was lower in males than in females and was independently correlated with poor clinical outcome. PPP2R3B codes for the PR70 protein, a regulatory substrate-recognizing subunit of protein phosphatase 2A. PR70 decreased melanoma growth by negatively interfering with DNA replication and cell cycle progression through its role in stabilizing the cell division cycle 6 (CDC6)-chromatin licensing and DNA replication factor 1 (CDT1) interaction, which delays the firing of origins of DNA replication. Hence, PR70 functionally behaves as an X-linked tumor suppressor gene.
Collapse
Affiliation(s)
- Léon C L van Kempen
- Department of Pathology, McGill University, Montreal, Quebec, Canada.,Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
| | - Margaret Redpath
- Department of Pathology, McGill University, Montreal, Quebec, Canada.,Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
| | - Mounib Elchebly
- Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
| | | | - Andreas I Papadakis
- Department of Pathology, McGill University, Montreal, Quebec, Canada.,Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
| | - James S Wilmott
- Melanoma Institute Australia, Royal Prince Alfred Hospital, and University of Sydney, Sydney, New South Wales, Australia
| | - Richard A Scolyer
- Melanoma Institute Australia, Royal Prince Alfred Hospital, and University of Sydney, Sydney, New South Wales, Australia
| | - Per-Henrik Edqvist
- Department of Immunology, Genetics and Pathology, and Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Fredrik Pontén
- Department of Immunology, Genetics and Pathology, and Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Dirk Schadendorf
- Department of Dermatology, University Hospital Essen, Essen, Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Anke F van Rijk
- Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
| | - Stefan Michiels
- Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.,Centre for Research in Epidemiology and Population Health (CESP), INSERM, UMR 1018, Université Paris-Sud, Kremlin-Bicetre, France
| | - Anne Dumay
- Centre de Recherche sur l'Inflammation, INSERM, UMR S 1149, Labex Inflamex, Université Paris-Diderot Sorbonne Paris-Cité, Paris, France
| | - Anne Helbling-Leclerc
- CNRS, UMR 8200, Université Paris-Sud, Villejuif, France.,CNRS UMR 8200, Universite Paris-Sud, Gustave Roussy, Villejuif, France
| | - Philippe Dessen
- Hématopoïèse normale et pathologique, INSERM UMR 1170, Université Paris-Sud, Gustave Roussy, Villejuif, France
| | - Jasper Wouters
- Laboratory of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.,Laboratory of Computational Biology, VIB Center for the Biology of Disease, KU Leuven, Leuven, Belgium.,Department of Human Genetics, KU Leuven, Leuven, Belgium
| | - Marguerite Stass
- Department of Surgical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Celia M T Greenwood
- Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.,Department of Oncology, McGill University, Montreal, Quebec, Canada.,Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada
| | - Ghanem E Ghanem
- Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Joost van den Oord
- Laboratory of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium
| | - Jean Feunteun
- CNRS UMR 8200, Universite Paris-Sud, Gustave Roussy, Villejuif, France
| | - Alan Spatz
- Department of Pathology, McGill University, Montreal, Quebec, Canada. .,Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.,Department of Oncology, McGill University, Montreal, Quebec, Canada
| |
Collapse
|
7
|
Kempen LCV, Redpath M, Elchebly M, Klein KO, Papadakis A, Willmott J, Scolyer R, Edqvist PH, Ponten F, Schadendorf D, Rjk AV, Michiels S, Dumay A, Helbling-Leclerc A, Dessen P, Wouters J, Stass M, Greenwood C, Ghanem GE, Oord JVD, Feunteun J, Spatz A. Abstract 5528: The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-5528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Male gender is independently and significantly associated with poor prognosis in melanoma of all clinical stages. The biological underpinnings of this sex difference remain largely unknown, but we hypothesize that gene expression from gonosomes may play an important role. The current study demonstrates that loss of the inactivated X chromosome in melanomas arising in females is strongly associated with poor distant metastasis-free survival, suggesting a dosage benefit of two X-chromosomes. The gonosomal PPP2R3B gene is located on the pseudo-autosomal region (PAR) of the X-chromosome in females and on the Y-chromosome in males. We observed that despite its location on the PAR that predicts equal dosage across genders, PPP2R3B expression is lower in males than in females, and is independently correlated with poor clinical outcome. PPP2R3B codes for the PR70 protein, a regulatory substrate recognizing subunit of PP2A, that decreases melanoma growth by negatively interfering with DNA replication and cell cycle progression through its role in stabilizing CDC6/CDT1 interaction that delays the firing of origins of DNA replication. As such, PR70 behaves functionally as an X-linked tumor suppressor gene.
Citation Format: Léon C.L. Van Kempen, Margaret Redpath, Mounib Elchebly, Kathleen Oros Klein, Andreas Papadakis, James Willmott, Richard Scolyer, Per-Henrik Edqvist, Fredrik Ponten, Dirk Schadendorf, Anke van Rjk, Stefan Michiels, Anne Dumay, Anne Helbling-Leclerc, Philippe Dessen, Jasper Wouters, Marguerite Stass, Celia Greenwood, G. Elias Ghanem, Joost van den Oord, Jean Feunteun, Alan Spatz. The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5528. doi:10.1158/1538-7445.AM2017-5528
Collapse
Affiliation(s)
| | | | - Mounib Elchebly
- 2Lady Davis Institute for Medical Research, Montréal, Quebec, Canada
| | | | - Andreas Papadakis
- 2Lady Davis Institute for Medical Research, Montréal, Quebec, Canada
| | - James Willmott
- 3Royal Prince Alfred Hospital and University of Sydney, New South Wales, Australia
| | - Richard Scolyer
- 3Royal Prince Alfred Hospital and University of Sydney, New South Wales, Australia
| | | | | | | | - Anke van Rjk
- 2Lady Davis Institute for Medical Research, Montréal, Quebec, Canada
| | | | - Anne Dumay
- 6Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | - Alan Spatz
- 1McGill University, Montréal, Quebec, Canada
| |
Collapse
|
8
|
Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M, de Thé H. p53 in breast cancer subtypes and new insights into response to chemotherapy. Breast 2013; 22 Suppl 2:S27-9. [DOI: 10.1016/j.breast.2013.07.005] [Citation(s) in RCA: 118] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
9
|
Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, Plassa LF, Cottu P, Marty M, André F, Sotiriou C, Pusztai L, de Thé H. Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer 2012; 132:1227-31. [PMID: 22886769 DOI: 10.1002/ijc.27767] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2012] [Accepted: 07/06/2012] [Indexed: 12/21/2022]
Abstract
Tumor protein p53 (TP53) is mutated in approximately 30% of breast cancers, but this frequency fluctuates widely between subclasses. We investigated the p53 mutation status in 572 breast tumors, classified into luminal, basal and molecular apocrine subgroups. As expected, the lowest mutation frequency was observed in luminal (26%), and the highest in basal (88%) tumors. Luminal tumors showed significantly higher frequency of substitutions (82 vs. 65%), notably A/T to G/C transitions (31 vs. 15%), whereas molecular apocrine and basal tumors presented much higher frequencies of complex mutations (deletions/insertions) (36 and 33%, respectively, vs. 18%). Accordingly, missense mutations were significantly more frequent in luminal tumors (75 vs. 54%), whereas basal tumors displayed significantly increased rates of TP53 truncations (43 vs. 25%), resulting in loss of function and/or expression. Interestingly, as basal tumors, molecular apocrine tumors presented with a high rate of complex mutations, but paradoxically, these were not associated with increased frequency of p53 truncation. As in luminal tumors, this could reflect a selective pressure for p53 gain of function, possibly through P63/P73 inactivation. Collectively, these observations point not only to different mechanisms of TP53 alterations, but also to different functional consequences in the different breast cancer subtypes.
Collapse
Affiliation(s)
- Anne Dumay
- Département de Biochimie, AP-HP, Hôpital Saint-Louis, Institut Universitaire d'Hématologie, CNRS UMR7212/INSERM U944/University Paris Diderot, Sorbonne Paris Cité, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, de CP, André F, Sotiriou C, Pusztai L, de TH. P2-02-09: TP53 Mutation Patterns in Breast Cancer Subgroups. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-02-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Tumor protein 53 (TP53) is the most commonly altered gene in human cancers. In breast cancers, TP53 is mutated in approximately 30% of all cases, but this frequency fluctuates widely within the different molecular subclasses. Different types of mutations may be observed, such as substitutions (replacement of a nucleotide pair by another one), or complex mutations (deletions or insertions of one or more nucleotides). Mutation types may reflect mechanism of DNA lesion or DNA repair deficiencies. Furthermore, mutations can give rise to different effects such as truncating mutations leading to loss of function, or missense mutations often leading to dominant negative activity. Those mutation effects can be advantageous in tumorigenesis and thus can be subject to selective pressure.
Here we classified 572 breast tumors in three groups, according to microarray data: luminal, basal and molecular apocrine. TP53 status was assessed by a yeast-based functional assay (FASAY) and cDNA sequencing. We then assessed whether any feature of TP53 mutations would be preferentially associated to a specific subtype of breast cancer.
- In term of TP53 mutation frequencies, as expected, lowest frequency was observed in luminal subgroup (26%) and highest in basal (90%) and molecular apocrine (70%). Notably, much higher rate of TP53 mutations occurred in luminal B subgroup (41%) than in luminal A one (17%), suggesting that TP53 may be an important feature in progression from luminal A to B.
- In term of mutations types, luminal tumors showed high frequency of substitutions, while molecular apocrine and basal presented increased rate of deletions and insertions, reflecting probably increased rate of DNA breaks. This suggests that same mutational events may occur in basal and molecular apocrine tumors.
- In term of mutation effects, we found high frequency of missense mutations in luminal tumors (notably AT to GC) and much higher rate of truncating mutations in basal tumors. These observations point to an existence of different selection pressure in each of them, such as a strong pressure for P53 mutations with potential dominant negative inhibition of P73/P63 (recently shown to favor invasion), in luminal tumors. Collectively, these results point not only to different mechanisms of P53 gene inactivation, but also different functional consequences among the different breast cancer subclasses.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-02-09.
Collapse
Affiliation(s)
- A Dumay
- 1Hôpital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, Belgium; MD Anderson Cancer Center, Houston
| | - J-P Feugeas
- 1Hôpital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, Belgium; MD Anderson Cancer Center, Houston
| | - E Wittmer
- 1Hôpital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, Belgium; MD Anderson Cancer Center, Houston
| | - J Lehmann-Che
- 1Hôpital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, Belgium; MD Anderson Cancer Center, Houston
| | - P Bertheau
- 1Hôpital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, Belgium; MD Anderson Cancer Center, Houston
| | - M Espié
- 1Hôpital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, Belgium; MD Anderson Cancer Center, Houston
| | - Cremoux P de
- 1Hôpital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, Belgium; MD Anderson Cancer Center, Houston
| | - F André
- 1Hôpital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, Belgium; MD Anderson Cancer Center, Houston
| | - C Sotiriou
- 1Hôpital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, Belgium; MD Anderson Cancer Center, Houston
| | - L Pusztai
- 1Hôpital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, Belgium; MD Anderson Cancer Center, Houston
| | - Thé H de
- 1Hôpital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, Belgium; MD Anderson Cancer Center, Houston
| |
Collapse
|
11
|
Feugeas JP, Dumay A, Lehmann-Che J, de CP, Delord M, Soulier J, Hamy AS, Espié M, André F, Marty M, Sotiriou C, Piccart-Gebhart M, Pusztai L, Bertheau P, de TH. P3-05-01: Gene Profiling of Histopathologically Characterized Apocrine Breast Cancers. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-05-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Breast cancer is currently classified in 3 groups based on estrogen receptor alpha (ER) and human epidermal growth factor receptor 2 (HER2/ERBB2) gene expression: one basal-like (ER-ERBB2-), one HER2−enriched (ERBB2+) and one luminal (ER+). Yet, in transcriptome-based classifications, ER-ERBB2+ group partially overlaps with more recently defined ER-AR+ (androgen receptor positive) group. This type was named molecular apocrine, in reference to the histopathologically characterized apocrine carcinomas (H-Apo), in which a marked activation of AR signaling was demonstrated with a distinct proteomic signature. H-Apo tumors correspond to 1% of invasive breast carcinomas and are clearly morphological distinct from other AR+ tumors. However, no specific H-Apo transcriptome signature has been reported for this sub-group. In an effort to better characterize those tumors, we have performed a meta-analysis of genomic data, focusing on the ER- AR+ breast subset.
Samples and Methods: Chips were from Affymetrix array generations HG-U133. 258 profiles were unpublished and 1145 were from published or in press data. Gene expression was carried out after GC-RMA normalization. Unsupervised hierarchical clustering and other statistical analysis were performed with R software.
Results: 160 of the 1403 investigated tumors were ER-AR+. An unsupervised hierarchical clustering clearly identified a small subgroup of 14 closely tumors expressing high transcripts levels of PIP, HPGD, ACSM1, AR, SDR5A1, HS3DB1. This profile was very similar to the proteomic signature previously described for the H-Apo tumors. In addition, the pathology report, although available only for 4 of those14 tumors, described them as typical apocrine carcinomas. Taken together, these data suggested that this cluster was the H-Apo subgroup. Unexpectedly, when using the transcriptomic PAM50 classification, 13 were classified as Luminal and only 1 as HER2−enriched, although the 14 tumors were all ER-negative. CGH analysis with Agilent 244K chips was carried out with 25 ER- AR+ tumors, of which 5 were H-Apo carcinomas. Importantly, those 5 H-Apo tumors exhibited fewer DNA lesions than the other ER-AR+ apocrine tumors (17% copy number alterations in H-Apo group versus 41%, p=0.02). More CGH data are currently under investigations and will be discussed.
Discussion: The histopathologically characterized apocrine carcinomas (H-Apo) display transcriptomic signs of active androgen metabolism and fewer DNA lesions than others molecular apocrine tumors. This could suggest that molecular apocrine and H-apocrine tumor derive from the same cell of origin, but that only H-Apo retains morphological apocrine features, possibly due to the presence of fewer genetic lesions. In any case, the prominent androgen signaling activation warrants functional assays of anti-androgen in these breast cancer subtypes.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-05-01.
Collapse
Affiliation(s)
- J-P Feugeas
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - A Dumay
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - J Lehmann-Che
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - Cremoux P de
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - M Delord
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - J Soulier
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - A-S Hamy
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - M Espié
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - F André
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - M Marty
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - C Sotiriou
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - M Piccart-Gebhart
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - L Pusztai
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - P Bertheau
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| | - Thé H de
- 1Hopital Saint-Louis, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Jules Bordet, Bruxelles, France; MD Anderson Cancer Center, Houston
| |
Collapse
|
12
|
Spatz A, van Kempen LC, Job B, Richon C, Barrois M, Dessen P, Lazar V, Michiels S, Helbling-Leclerc A, Dumay A, Petrella T, Batist G, Stas M, Schadendorf D, van den Oord J, Feunteun J. Abstract 4835: Gonosome-linked expression of PPP2R3B in cutaneous melanoma correlates with distant metastasis free survival. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-4835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A strong adverse male effect for melanoma incidence and survival has been reported. No biological explanation, including hormonal differences, has been identified so far. We hypothesize that this gender difference in incidence and survival involves X-linked tumor suppressor genes and/or oncogenes whose expression is affected by X-chromosome alterations.
Methods: DNA and RNA were extracted from 49 fresh frozen primary melanomas (32 females, 17 males, distant metastasis free survival (DMFS) <3 years or follow up >3 years) and subjected to array-based comparative genomic hybridization. Supervised and unsupervised cluster analyses were performed. X-inactivation was studied by Xist RNA in situ hybridization and androgen receptor methylation-sensitive PCR. The expression of a candidate X-linked gene was analyzed by quantitative PCR and correlated with DMFS in uni- and multivariate analyses.
Results: Supervised cluster analyses revealed distinct DNA signatures associated with clinical and histopathological characteristics. Unsupervised clustering identified three groups of which one was composed of predominantly female patients (10/13) and associated with the worst DMFS. This group was characterized by loss of one X-chromosome in 7 of the 13 patients. Loss of X correlated with poor DMFS of female patients (logrank p=0.009). Intriguingly, the lost X chromosome was systematically the inactivated copy. Among the 17 males, Y-chromosome loss correlated with DMFS (logrank p=0.015). We found that the PPP2R3B gene, located within one of the pseudoautosomal regions and thus not inactivated on the inactive X in females, is lost from the Y in males. PPP2R3B encodes a regulatory subunit of protein phosphatase 2 that may negatively control cell proliferation via targets such as CDC6 or RB. Quantitative analysis of PPP2R3B mRNA expression in an independent sample set of melanomas revealed a strong correlation between decreased levels of PPP2R3B expression and poor DMFS irrespective of gender in multivariate analysis (p=0.0007).
Conclusion: Our analyses reveal a specific pattern of X and Y chromosome losses that are associated with melanoma progression. PPP2R3B is a potential gonosome-linked tumor suppressor gene, whose loss of expression correlates with poor DMFS.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4835. doi:10.1158/1538-7445.AM2011-4835
Collapse
Affiliation(s)
- Alan Spatz
- 1McGill University, Montreal, Quebec, Canada
| | | | | | | | | | | | | | | | | | - Anne Dumay
- 2Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | |
Collapse
|
13
|
|
14
|
Spatz A, Richon C, Job B, Michiels S, Dumay A, Barrois M, Schadendorf D, Eggermont AM, Dessen P, Van den Oord JJ. Association of critical losses in X chromosome with melanoma progression: An EORTC Melanoma group study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Dumay A, Rincheval V, Trotot P, Mignotte B, Vayssière JL. The superoxide dismutase inhibitor diethyldithiocarbamate has antagonistic effects on apoptosis by triggering both cytochrome c release and caspase inhibition. Free Radic Biol Med 2006; 40:1377-90. [PMID: 16631528 DOI: 10.1016/j.freeradbiomed.2005.12.005] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2005] [Revised: 11/24/2005] [Accepted: 12/07/2005] [Indexed: 12/17/2022]
Abstract
Tumor necrosis factor-alpha (TNF-alpha) and etoposide both trigger a large and rapid production of reactive oxygen species (ROS) in HeLa cells. This occurs before translocations of the proapoptotic Bax and cytochrome c proteins, the loss of mitochondrial membrane potential (DeltaPsim), and apoptosis. We have used diethyldithiocarbamate (DDC), a well-known inhibitor of Cu, Zn superoxide dismutase to study the role of ROS in this system. We report that DDC strongly inhibits caspase activation, loss of DeltaPsim, and cell death induced by TNF-alpha or etoposide. Surprisingly, DDC does not inhibit Bax and cytochrome c translocations. On the contrary, we have observed that DDC can trigger the translocations of these proteins by itself, without altering DeltaPsim. Here, we report that DDC has at least two antagonistic apoptosis regulation functions. First, DDC triggers ROS-dependent Bax and cytochrome c translocations, which are potentially proapoptotic, and second, DDC inhibits caspase activation and activity, loss of DeltaPsim, and cell death, in a ROS-independent manner. Our results suggest an interesting model in which ROS-dependent Bax and cytochrome c translocations can be studied without interference from later apoptotic events.
Collapse
Affiliation(s)
- Anne Dumay
- Université de Versailles/St. Quentin-en-Yvelines, CNRS FRE-2445, Laboratoire de Génétique et Biologie cellulaire, Versailles, France
| | | | | | | | | |
Collapse
|
16
|
Dumay A, Laulier C, Bertrand P, Saintigny Y, Lebrun F, Vayssière JL, Lopez BS. Bax and Bid, two proapoptotic Bcl-2 family members, inhibit homologous recombination, independently of apoptosis regulation. Oncogene 2006; 25:3196-205. [PMID: 16407825 DOI: 10.1038/sj.onc.1209344] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
In order to analyse the relationships between regulation of apoptosis and homologous recombination (HR), we overexpressed proapoptotic Bax or only-BH3 Bid proteins or antiapoptotic Bcl-2 or Bcl-XL, in hamster CHO cells or in SV40-transformed human fibroblasts. We measured HR induced by gamma-rays, UVC or a specific double-strand cleavage targeted in the recombination substrate by the meganuclease I-SceI. We show here that the induction of both recombinant cells and recombinant colonies was impaired when expressing Bcl-2 family members, in hamster as well as in human cells. Moreover, the pro- as well as antiapoptotic Bcl-2 family members inhibited HR, independently of degradation of the RAD51 recombination protein and of their impact on apoptosis. These data reveal a mechanism of HR downregulation by potentially proapoptotic proteins, distinct from and parallel to degradation of recombination proteins, a situation that should also optimize the efficiency of programmed cell death.
Collapse
Affiliation(s)
- A Dumay
- UMR 217 CNRS/CEA, DSV, DRR, Fontenay aux Roses Cédex, France
| | | | | | | | | | | | | |
Collapse
|
17
|
Abstract
DNA double-strand breaks (DSBs) are the major lethal lesion induced by ionizing radiation or by replication block. However, cells can take advantage of DSB-induced recombination in order to generate genetic diversity in physiological processes such as meiosis and V(D)J recombination. Two main alternative pathways compete for DSB repair: homologous recombination (HR) and non-homologous end-joining (NHEJ). This review will briefly present the mechanisms and the enzymatic complex for HR and NHEJ. The signalling of the DSB through the ATM pathway will be presented. Then, we will focus on the case of the RAD51 protein, which plays a pivotal role in HR and is conserved from bacteria to humans. Post-translational regulation of RAD51 is presented. Two contrasting situations are discussed: one with up-regulation (expression of the oncogene BCR/ABL) and one with a down-regulation (expression of the oncogene BCL-2) of RAD51, associated with apoptosis inhibition and tumour predisposition.
Collapse
Affiliation(s)
- Fayza Daboussi
- UMR CEA/CNRS 217, CEA, Div des Sciences du Vivant, DRR, 60-68 Avenue du Général Leclerc, 92265, Fontenay-aux-Roses, Cedex, France
| | | | | | | |
Collapse
|
18
|
Abstract
The oncogenic role of Bcl-2 is generally attributed to its protective effect against apoptosis. Here, we show a novel role for Bcl-2: the specific inhibition of the conservative RAD51 recombination pathway. Bcl-2 or Bcl-X(L) overexpression inhibits UV-C-, gamma-ray- or mutant p53-induced homologous recombination (HR). Moreover, Bcl-2 recombination inhibition is independent of the role of p53 in G1 arrest. At an acute double-strand break in the recombination substrate, Bcl-2 specifically inhibits RAD51-dependent gene conversion without affecting non-conservative recombination. Bcl-2 consistently thwarts recombination stimulated by RAD51 overexpression and alters Rad51 protein by post-translation modification. Moreover, a mutant (G145A)Bcl-2, which is defective in Bax interaction and in apoptosis repression, also inhibits recombination, showing that the death and recombination repression functions of Bcl-2 are separable. Inhibition of error-free repair pathways by Bcl-2 results in elevated frequencies of mutagenesis. The Bcl-2 gene therefore combines two separable cancer-prone phenotypes: apoptosis repression and a genetic instability/mutator phenotype. This dual phenotype could represent a mammalian version of the bacterial SOS repair system.
Collapse
Affiliation(s)
| | | | | | - Bernard S. Lopez
- UMR217 CNRS-CEA, CEA, Direction des Sciences du Vivant, Département de Radiobiologie et Radiopathologie, 60–68 Avenue du Général Leclerc, 92 265 Fontenay aux Roses, Cedex, France
Corresponding author e-mail:
Y.Saintigny and A.Dumay contributed equally to this work
| |
Collapse
|
19
|
Youinou P, Le Goff P, Dumay A, Lelong A, Fauquert P, Jouquan J. The antiperinuclear factor. I. Clinical and serologic associations. Clin Exp Rheumatol 1990; 8:259-64. [PMID: 1696191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The antiperinuclear factor (APF) test raises two main problems: the unpredictability of the cells used as substrate and the difficulty in expressing the results. We propose that 10% of the cells have to be stained by a given serum in order for it to be considered positive. APF were found to be present in 76% of rheumatoid arthritis (RA) patients, 3% of healthy controls and occasionally in disease controls. The production of APF was significantly (p less than 0.01) related to the presence of rheumatoid factor in RA, and IgG antibody was predominant in the APF test.
Collapse
Affiliation(s)
- P Youinou
- Department of Immunology, Brest University Medical School Hospital, France
| | | | | | | | | | | |
Collapse
|
20
|
Youinou P, Seigneurin JM, Le Goff P, Dumay A, Vicariot M, Lelong A. The antiperinuclear factor. II. Variability of the perinuclear antigen. Clin Exp Rheumatol 1990; 8:265-9. [PMID: 2165883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Since the antiperinuclear factor (APF) test on human buccal cells is rather unpredictable, we have investigated the possible factors determining the expression of appropriate antigens by the cells. We failed to find any relationship of the expression of perinuclear antigens to the donor's smoking habits, the degree of contamination with saprophytic bacteria, the presence or absence of blood group substances in saliva, or the titers of serum antibodies to Epstein-Barr virus. Family studies were also performed to further elucidate a genetic predisposition to the expression of the APF antigen.
Collapse
Affiliation(s)
- P Youinou
- Department of Immunology, Brest University Medical School Hospital, France
| | | | | | | | | | | |
Collapse
|
21
|
Youinou P, Delecoeuillerie G, Fauquert P, Lelong A, Dumay A, Le Goff P. [Tiopronin, an example of hydrosulphonated derivatives used in the treatment of rheumatoid polyarthritis. Study of immunologic effects]. Rev Rhum Mal Osteoartic 1990; 57:287-91. [PMID: 1971455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Fifteen patients with rheumatoid arthritis were treated with tiopronine, and an immunological check-up carried out before the onset and after a two-month treatment. The latex test titres decreased, and there was a significant fall in the levels of IgA-containing circulating immune complexes, in parallel with a depletion of plasma complement breakdown products. Patients displayed a decrease in CD8+T cells and in CD4+Leu 8-T cells and a high proportion of activated T lymphocytes. This returned to normal after treatment. Treatment with TP led also to a reduction of adherence and chemotaxis of polymorphonuclear cells.
Collapse
Affiliation(s)
- P Youinou
- Laboratoire d'Immunologie, CHRU, Brest
| | | | | | | | | | | |
Collapse
|